Treatment sequence network-meta analysis in Crohn's disease: a methodological case study.

CONCLUSIONS: The NMA suggest that ustekinumab is associated with the highest likelihood of reaching response or remission at 1 year compared with placebo, adalimumab, and vedolizumab. Results should be interpreted with caution because this is a novel methodology; however, the treatment sequence analysis may be the most methodologically sound analysis to derive estimates of comparative efficacy in CD in the absence of head-to-head evidence. PMID: 30727745 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30727745?dopt=Abstract

Source: Current Medical Research and Opinion - February 9, 2019 Category: Research Tags: Curr Med Res Opin Source Type: research